RxDoctor Payments Data

Gordon Mitchell, MD

Cardiovascular Disease · Bryan, TXNPI 1740258508

Payments from drug & device makers

$10,240in general payments, 2019–2025

Across 670 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Medtronic$1K
  • Novartis$933
  • E.r. Squibb & Sons, L.L.C.$800
  • Johnson & Johnson$471
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,221100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,240 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$558,166
Medicare patients
753
Services billed
5,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban469$517,790
Repatha SureclickEvolocumab385$295,457
EntrestoSacubitril/Valsartan236$256,338
MultaqDronedarone Hcl108$161,373
Repatha SyringeEvolocumab119$76,216
JardianceEmpagliflozin78$65,812
XareltoRivaroxaban34$43,723
VascepaIcosapent Ethyl48$29,252
Praluent PenAlirocumab50$26,102
NexlizetBempedoic Acid/Ezetimibe13$14,086
Atorvastatin Calcium1,085$10,902
Metoprolol Succinate608$10,357
Ezetimibe342$8,488
LivaloPitavastatin Calcium17$7,648
Ranolazine ErRanolazine76$7,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$313$517,790469 claims
NovartisEntresto$933$256,338236 claims
Sanofi-aventis U.S. LLCMultaq$213$161,373108 claims
Boehringer IngelheimJardiance$67$65,81278 claims
Johnson & JohnsonXarelto$471$43,72334 claims
Esperion Therapeutics, Inc.Nexlizet$345$14,08613 claims
Kowa Pharmaceuticals America, Inc.Livalo$31$7,64817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →